X

Oncologist

Oncologist
Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

The study demonstrates a significant improvement in overall survival with an estimated median OS of 10.9 months in the nivolumab arm compared with 8.4 months in the chemotherapy arm.

Oncologist
04/01/2021
Providing Supportive and Palliative Care Using Telemedicine for Patients with Advanced Cancer During the COVID-19 Pandemic in Mexico

This study reported the results of a multidisciplinary patient-navigator-led telemedicine supportive care program in Mexico City.

Oncologist
10/22/2020
All in the Levels- Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Gastrointestinal Cancer Patients.

ICIs benefit patients with rare subsets of GI cancer. Significant interest exists to identify predictive biomarkers that may increase the applicability of ICI therapy for these patients.

Oncologist
09/18/2020
Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies.

This study aimed to assess the...

Oncologist
09/22/2020
Subscribe to Oncologist

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39